Telix Pharmaceuticals Valuation
| TLX Stock | 24.94 0.11 0.44% |
At this time, the company appears to be undervalued. Telix Pharmaceuticals has a current Real Value of USD28.0 per share. The regular price of the company is USD24.94. Our model measures the value of Telix Pharmaceuticals from inspecting the company fundamentals such as Shares Outstanding of 334.72 M, return on equity of 0.2, and Operating Margin of 0.09 % as well as reviewing its technical indicators and probability of bankruptcy.
Price Book 20.6648 | Enterprise Value 8.3 B | Enterprise Value Ebitda 113.0847 | Price Sales 13.235 | Forward PE 77.5194 |
Undervalued
Today
Please note that Telix Pharmaceuticals' price fluctuation is very steady at this time. Calculation of the real value of Telix Pharmaceuticals is based on 3 months time horizon. Increasing Telix Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Telix Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 24.94, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 24.94 | Real 28.0 | Hype 24.76 | Naive 24.68 |
The intrinsic value of Telix Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Telix Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Telix Pharmaceuticals helps investors to forecast how Telix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Telix Pharmaceuticals more accurately as focusing exclusively on Telix Pharmaceuticals' fundamentals will not take into account other important factors: Telix Pharmaceuticals Cash |
|
Telix Pharmaceuticals Total Value Analysis
Telix Pharmaceuticals is at this time anticipated to have takeover price of 8.25 B with market capitalization of 8.55 B, debt of 17.45 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Telix Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
8.25 B | 8.55 B | 17.45 M |
Telix Pharmaceuticals Investor Information
About 41.0% of the company outstanding shares are owned by corporate insiders. The company had not issued any dividends in recent years. Based on the key indicators related to Telix Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Telix Pharmaceuticals is performing exceptionally good at this time. It has a great odds to report excellent financial results in January.Telix Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Telix Pharmaceuticals has an asset utilization ratio of 124.69 percent. This implies that the Company is making USD1.25 for each dollar of assets. An increasing asset utilization means that Telix Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.Telix Pharmaceuticals Ownership Allocation
Telix Pharmaceuticals shows a total of 334.72 Million outstanding shares. Telix Pharmaceuticals maintains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Telix Pharmaceuticals Profitability Analysis
The company reported the revenue of 496.66 M. Net Income was 5.21 M with profit before overhead, payroll, taxes, and interest of 98.54 M.About Telix Pharmaceuticals Valuation
The stock valuation mechanism determines Telix Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Telix Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Telix Pharmaceuticals. We calculate exposure to Telix Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Telix Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 308.5 M | 323.9 M |
Additional Tools for Telix Stock Analysis
When running Telix Pharmaceuticals' price analysis, check to measure Telix Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telix Pharmaceuticals is operating at the current time. Most of Telix Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Telix Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telix Pharmaceuticals' price. Additionally, you may evaluate how the addition of Telix Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.